Objective: Two strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients. Design: Omnitrope 3.3 mg/ml solution or Omnitrope 6.7 mg/ml solution was compared to Omnitrope 5 mg/ml powder and Genotropin 5 mg/ml powder in terms of pharmacokinetics, pharmacodynamics, safety, and local tolerance after a single s.c. dose of 5 mg. Methods: Two randomized, double-blind, single-dose, three-way crossover studies were carried out in 36 young healthy volunteers each. Endogenous GH secretion was suppressed with a 25-h continuous i.v. infusion of octreotide (40 mg/h) starting 1 h before rhGH administration. Results: Pharmacokinetic parameters were similar for the three treatments in both studies respectively. Bioequivalence criteria were met for area under the concentration-time curve (AUC) and C max . Likewise, the pharmacodynamic parameters for IGF1, IGF-binding protein 3, and non-esterified fatty acid were similar for all preparations. No differences in adverse events were observed between groups. Conclusions: Omnitrope 3.3 mg/ml solution, 6.7 mg/ml solution, and 5 mg/ml powder, and Genotropin 5 mg/ml powder are bioequivalent, have similar pharmacokinetic and pharmacodynamic profiles, and are equally safe. Overall, the products can be considered to be therapeutically interchangeable.
Introduction
Prior to the introduction of recombinant human GHs (rhGHs) in the 1980s, extracts from human pituitary glands (pithGH) have been used to treat GH deficiency, mainly in pituitary dwarfism. Availability, purification, standardization, immunogenicity, microbial safety, and especially the cumulative appearance of CreutzfeldtJakob disease were the major limitations of this approach (1, 2) . Therefore, the development of rhGH preparations and their first use in 1981 were major therapeutic advances, and also enabled the broader use of rhGH in other diseases with deficient endogenous GH production, in insulin-like growth factor 1 (IGF1) resistance (e.g. Turner syndrome), and in growth disturbances due to other diseases (3, 4) .
High costs of rhGH treatment, however, cause a considerable burden for individuals and health systems, or even exclude patients from their required treatment. Thus, there is considerable public interest in the availability of affordable rhGH products, especially after the patent of the originator rhGH products has expired, with the new products being tailored for the individual use (5) (6) (7) . For small molecules, the standard bioequivalence approach has been developed and applied successfully for decades to assess therapeutic interchangeability of two preparations with one chemically identical active component (8) . Since biopharmaceuticals differ from small-molecule drugs in complexity and proof of essential similarity cannot be achieved in such products (9) , the bioequivalence approach was modified for biopharmaceuticals, and the concept of 'biosimilarity' was introduced indicating that the products are considered to be similar in terms of quality, safety, and efficacy (10) (11) (12) . Biosimilar in the case of recombinant proteins generally means that preparations contain the same protein backbone according to the amino acid sequence, have similar pharmacokinetic and pharmacodynamic properties, exhibit a similar safety profile and similar therapeutic efficacy tested in accurate clinical studies, and therefore, can be considered interchangeable (11, 13) .
The products still may have subtle structural and physicochemical differences attributable e.g. to posttranslational modification, complex formation, or degradation resulting in different distribution of (micro) heterogeneity of the individual preparations (11, 12) . To define acceptance criteria, the European Medicines Agency (EMEA) developed general guidelines on biosimilar drugs (14-16) as well as specific guidelines for individual biosimilar substances including rhGH (17, 18) .
The rhGH products studied here, i.e. Omnitrope and Genotropin, have the same amino acid sequence which is identical to that of natural hGH. The therapeutic effects of GH are mediated by IGF1 (19) . IGF1-binding proteins (IGFBPs) play important regulatory roles in controlling the bioavailability and action of IGF1, and are regulated by various factors including GH (20, 21) . About 90% of IGF1 is bound to IGFBP3. Because rhGH preparations induce significant increases in IGF1, IGFBP3, and non-esterified fatty acid (NEFA) (22) related to GH mechanism of action, these molecules are accepted as pharmacodynamic (PD) parameters for GH activity; however, the spurious relationship between serum IGF1 levels and growth response precludes the use of IGF1 as a surrogate marker for efficacy (17) .
Omnitrope has been developed as a similar biological medicinal product (biosimilar) with Genotropin as the reference product, based on a concise clinical program consisting of phase I studies and phase III studies according to the respective guidelines. In 2006, marketing authorization for Omnitrope 5 mg/ml powder for solution for injection (Omnitrope 5 P) was granted by both the EMEA and the FDA. To extend the usability of Omnitrope and to increase the convenience for patients, a ready-to-use Omnitrope 3.3 mg/ml solution for injection (Omnitrope 3.3 S) and also a higher concentrated liquid preparation of Omnitrope containing 6.7 mg of rhGH per ml (Omnitrope 6.7 S) were developed. Equivalent therapeutic efficacy and clinical comparability in terms of safety and immunogenicity of Omnitrope 5 P with Genotropin 5 mg/ml powder (Genotropin 5 P) and Omnitrope 3.3 S have already been reported in a limited set of clinical studies (23) . The purpose of the present two studies was to demonstrate the bioequivalence of the two novel rhGH liquid preparations, Omnitrope 3.3 S and Omnitrope 6.7 S, with the commercial powder preparations Omnitrope 5 P and Genotropin 5 P, and to demonstrate the comparability in terms of pharmacokinetic (PK), PD, safety, and local tolerance after a single s.c. dose of 5 mg of each product in healthy subjects.
Methods

Study design
For each of the two novel Omnitrope liquid preparations -Omnitrope 3.3 S and Omnitrope 6.7 S -a separate randomized, double-blind, single-dose, three-way crossover study was carried out in 36 healthy volunteers (studies A and B respectively). In both studies, in addition to the respective novel preparation, both marketed Omnitrope and Genotropin 5 mg/ml powder preparations were included as references. The studies were conducted in healthy, young, non-smoking, Caucasian male or female subjects. Both studies were conducted according to the revised Declaration of Helsinki and GCP guidelines, and were approved by the pertinent ethics committee and the regulatory authorities. All individuals examined during the study gave their written informed consent. Eligibility was based on extensive examinations including physical examination, clinical chemistry, urinalysis, electrocardiogram (ECG) recording, vital signs, tests for substance abuse, and pregnancy. For both studies, study procedures were the same in each of the three treatment periods, which were separated by a 7-day washout period between the rhGH administrations. Subjects underwent a full physical and safety examination with standard clinical laboratory evaluation, urinalysis, ECG, virology, toxicology, and alcohol screening, and in addition, a pregnancy test was done for female subjects at the screening examination and also 14 days after the last dosing. Healthy male and female volunteers who met the inclusion/exclusion criteria were randomized to one of the six possible treatment sequences. The subjects were confined to the study center from the evening prior to each treatment period until blood sampling 24 h after rhGH administration, which was done after overnight fasting. Upon admission to the ward, a baseline evaluation was done including eligibility, concomitant medications, safety, toxicology, and alcohol screening, and again, a pregnancy test was done for female subjects in addition to that described above. One hour before the administration of rhGH, a 25-h continuous i.v. infusion of octreotide (40 mg/h; a somatostatin analog, Sandostatin, Novartis Pharma AG, Basel, Switzerland) was started. This schedule is effective to almost completely suppress endogenous GH secretion (Sandoz GmbH, Kundl, Austria, data on file).
Blood sampling for hGH and NEFA analyses was performed at K1.0, K0.5, 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 h relative to rhGH administration, while samples for IGF1 and IGFBP3 analyses were drawn at K1.0, K0.5, 0, 12, 16, 24, 48, 72, and 96 h. Vital signs were measured repeatedly during the sampling period, and further safety checks were done 96 h after dosing. Nutrition was standardized during the in-house period. Adverse events and use of any concomitant medications were recorded at 12, 24, 48, 72, and 96 h relative to rhGH administration, and at the final followup visit. In each treatment period, local tolerance was assessed 5 min and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 h after dosing. Local tolerance was evaluated by the subjects using a 100-mm visual analogue scale (VAS) for pain, and by the assessor using an injection site reaction (ISR) score (grading from 0Z no reaction to 3Z severe harm).
Study medication
The intended dose of rhGH in all cases was 5.00 mg. Omnitrope 5 mg/ml powder preparations (5 P) and Omnitrope ready-to-use solution preparations (3.3 S and 6.7 S) were manufactured by Sandoz GmbH. Genotropin 5 mg/ml powder preparation (5 P) was purchased from Pfizer Pharma GmbH, Karlsruhe, Germany. The ready-to-use solutions were administered as such, while the powder preparations were reconstituted prior to administration according to the respective method as registered. Accordingly, scheduled volumes for administration were 1.50 ml for Omnitrope 3.3 S, 0.75 ml for Omnitrope 6.7 S, and 1.00 ml for the reconstituted powder preparations of Omnitrope 5 P and Genotropin 5 P (given in both studies). Administration was via the s.c. route to the lower abdomen. Syringes used in the studies were weighed before and after administration to detect potential differences between the intended and the actually administered dose possibly caused by slight variations in drug reconstitution and administration technique. 
Sample size and study populations
The sample size was calculated using the standard bioequivalence methods and boundaries (80-125% for 90% confidence interval (CI) of AUC last and C max ratios). Based on a previous bioequivalence study, intra-subject coefficients of variation of 20% for C max and 10% for AUC last and a true ratio of means between 95 and 105% were assumed. A total sample size of 30 subjects was thus considered sufficient to show bioequivalence between all three pairs of treatments simultaneously, with an overall power of at least 80% including adjustment for the multiple testing. Anticipating a drop-out rate of up to 20%, a total number of 36 subjects were dosed for each study.
In study A, 30 male and 6 female volunteers were included. The mean (S.D.) age was 27.4 (5.1) years, body weight 70.6 (11.1) kg, body height 174 (8) cm, and body mass index (BMI) 23.1 (2.5) kg/m 2 . One of the 36 randomized subjects was prematurely withdrawn from the study for not appearing for the second treatment period. Thus, 35 subjects were included in the PK/PD evaluations (per-protocol-population). In study B also, 30 male and 6 female volunteers were included. The mean (S.D.) age was 27.1 (5.1) years, body weight 69.1 (9.2) kg, body height 174 (7) cm, and BMI 22.7 (2.1) kg/m 2 . Two of the subjects withdrew from the study prematurely after period 1 for personal reasons, and for two subjects, deviations of the syringe weights of more than G3 S.D. of the mean weights were observed, leading to an exclusion of four subjects from the per-protocol-population.
Analytical methods
Blood samples were allowed to clot at room temperature. Serum was obtained by centrifugation, and stored at %K20 8C until analysis. The concentrations of hGH, IGF1, and IGFBP3 in serum were measured using the respective commercially available and fully validated chemiluminescent immunometric assay kits of the Immulite 2000 series with the Immulite 2000 Analyzer (DPC Biermann GmbH, Bad Nauheim, Germany). The lower limit of quantification (LLOQ) was 0.2 ng/ml for GH, 25 ng/ml for IGF1, and 500 ng/ml for IGFBP3. The concentration of NEFA in serum was measured using a commercially available and fully validated assay kit obtained from Wako Chemicals GmbH (Neuss, Germany). The LLOQ was 100 nmol/ml. The assays were additionally validated according to the requirements of the FDA guideline for bioanalytical method validation (24) . Within the validation, the accuracy and precision (intra-and inter-assay), linearity, LLOQ, and stability of the different parameters (freeze thaw, short term (room temperature and 2-8 8C up to 4 h), and long term for up to 3 months) were tested. All validation parameters fulfilled the acceptance criteria based on the guideline.
Calculation of PK and PD parameters and statistical evaluation
Parameters were calculated from the serum concentration versus actual sampling time profiles of GH (PK parameters) and of IGF1, IGFBP3, and NEFA (PD parameters) by standard non-compartmental methods using the WinNonlin software (version 4.1, Pharsight 
Results
Individual GH serum concentration versus time profiles (Figs 1 and 2 ) and the derived PK parameters (Table 1) were found to be very similar for the three rhGH preparations within each of the two studies. Standard bioequivalence criteria were met for AUC and C max , i.e. the respective 90% CIs for the ratios of the means were within the 0.80-1.25 range for each of the pairwise comparisons (Table 2) . In study A, albeit within the bioequivalence range, concentrations and derived PK parameters were significantly (aZ10%) higher for the Genotropin preparation, as could be expected from GH (µg/l) Genotropin 5 P Omnitrope 5 P Omnitrope 6.7 S Figure 2 Study B: GH serum levels (meanGS.D.) after a single s.c. injection of Genotropin 5 mg/ml powder (black boxes), Omnitrope 5 mg/ml powder (white triangles), and Omnitrope 6.7 mg/ml solution (white circles). 35 (18) 39 (11) (Table 3 ) of the secondary parameters IGF1, IGFBP3, and NEFA of the three rhGH preparations were also found to be comparable, based on the corresponding 95% CIs for the ratios of the respective parameters (Table 4) .
Local tolerability did not provide any surprising results for a s.c. injection of rhGH. As expected, the results for pain rating by the subjects at the site of the rhGH administration were clustered near the far left-hand side of the 100 mm VAS (no pain). The highest reported pain ratings were immediately following injection. The mean rating in study A (results of study B given in parentheses) was 9.5G9.3 mm following Omnitrope 3.3 S injection (9.0G8.1 mm following Omnitrope 6.7 S injection), 6.8G5.6 mm (5.3G5.9 mm) following Omnitrope 5 P injection, and 17.3G14.7 mm (11.3G10.2 mm) following Genotropin 5 P injection. The mean pain rating was below 1.0 mm for all three treatments by 2 h (study A) and by 30 min (study B) after the rhGH administration. ISR scores determined by the investigator at the same time points were none or mild for all treatments with no discernable difference between the products. Most reactions were reported within the first 30 min of injection.
The most frequently reported adverse events were abdominal pain (experienced by 50.0% of subjects in study A and by 38.9% subjects in study B), headache (28.3/33.3%), diarrhea (19/25.0%), Table 2 Results of confirmative comparisons for primary pharmacokinetic parameters AUC last and C max (PP populations).
AUC last ratio of LS-means (90% CI)
C max ratio of LS-means (90% CI) in study B) . The causal relationship of these adverse events (AEs) was rated as being unlikely or unrelated in more than 95% of the events in both studies. Intensity of the AEs was rated as mild in roughly 60% of the cases and as severe in less than 5%. Of the eight severe AEs, five were episodes of headache, one was an episode of nasopharyngitis, one was an episode of abdominal pain, and one was a urinary tract infection. All treatment groups were similar in the number, type, and intensity of adverse events. None of the observed AEs was unexpected.
Discussion
Omnitrope 5 mg/ml lyophilized powder for reconstitution received market authorization in Europe on the basis of the first ever biosimilar approval in 2006. The reference product is Genotropin 5 mg/ml lyophilized powder for reconstitution. Two strengths of a novel ready-to-use liquid preparation of Omnitrope were developed to simplify the handling for the patients, and to make the injection procedure less timeconsuming. It also represents the first-line extension of a biosimilar product, and illustrates how biosimilar development may stimulate further innovation of biological product development.
Pharmacokinetics
The present studies demonstrate the bioequivalence of the two novel liquid rhGH preparations Omnitrope 3.3 mg/ml solution and Omnitrope 6.7 mg/l solution to the marketed Omnitrope 5 mg/ml powder and Genotropin 5 mg/ml powder preparations, and confirm the bioequivalence of the latter two original preparations. The study design is in agreement with the respective EMEA guideline on GH (17) . Single-dose pharmacokinetics, namely AUC, C max , and terminal elimination half-life, are the main criteria to assess similarity with respect to pharmacokinetics and pharmacodynamics. The use of the classical criteria of bioequivalence, i.e. 90% CI for the estimated ratios for AUC and C max within the 80-125% boundaries, is justified on the basis of the known intra-individual variability of 10-20%.
Pharmacodynamics
IGF1 is the preferred pharmacodynamic marker for the activity of somatropin and is, together with IGFBP3, recommended to be used in comparative pharmacodynamic studies (17) . The results of the phase I studies demonstrated that s.c. administration of 5 mg of Omnitrope 3.3 mg/ml solution, Omnitrope 6.7 mg/l solution, Omnitrope 5 mg/ml powder, and Genotropin 5 mg/ml powder has similar pharmacokinetic and pharmacodynamic profiles. The sensitivity of the IGF1, IGFBP3, and NEFA parameters has its limitations to detect differences. Although NEFA serum levels show a significant rise after GH administration, the changes in IGF1 and IGFBP3 serum levels brought about by rhGH at the dose tested are relatively low compared with baseline concentrations (26) . The increase in serum levels of IGF1 stayed within the upper normal range, and did not accumulate to reach acromegalic values after the single-dose rhGH administration (27) . Furthermore, based on the law of mass action, changes in pharmacodynamic parameters are almost always much less than those in pharmacokinetic parameters. Finally, concentrations of IGF1 and IGFBP3 were taken into account until 96 h after somatropin administration, whereas somatostatin infusion was stopped 24 h post dosing. Nevertheless, the results of the present studies unequivocally show that there are no meaningful differences between the preparations in any respect for all the parameters tested, and that the pharmacodynamic profiles are similar.
Side effects
The most frequently reported adverse events were those affecting the gastrointestinal system, which were mainly considered to be a side effect of octreotide. Therefore, it is difficult to assess whether rhGH treatment might also contribute to these complaints in this setting as described earlier (26, 28) . Nevertheless, adverse events were similar regarding the number, type, and intensity in all treatment groups. None of the observed AEs was unexpected.
Conclusions
Two strengths of a novel ready-to-use liquid preparation of Omnitrope were developed to increase the convenience for the patients. Omnitrope 3.3 mg/ml and Omnitrope 6.7 mg/ml ready-to-use solutions fulfill the criteria for bioequivalence compared with the original Omnitrope 5 mg/ml powder and Genotropin 5 mg/ml powder preparations. All products exhibit similar pharmacokinetic and pharmacodynamic profiles, and are equally safe and well tolerated. Together with published data on clinical efficacy (23) and based on current knowledge, these results suggest that the ready-to-use liquid rhGH products are therapeutically interchangeable, while providing a higher level of convenience for the patients. In the meantime, these products are registered in the European Union, the United States, Canada, Australia, and Japan.
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